Putrescine-dependent invasive capacity of rat ascites hepatoma cells.
The effects of inhibitors of polyamine synthesis on the invasive capacity of rat ascites hepatoma (LC-AH) cells were examined by in vitro assay of penetration of the LC-AH cells through a monolayer of calf pulmonary arterial endothelial (CPAE) cells. Pretreatment of LC-AH cells with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, before seeding them onto a CPAE cell monolayer and culturing them for 24 h in the absence of DFMO decreased the number of penetrating tumor cells time and dose dependently (about 35% of the maximal inhibition) without affecting their viability or proliferative activity. DFMO treatment caused a marked decrease in the intracellular level of putrescine but not of spermidine or spermine. The DFMO-induced decreases in invasive capacity and putrescine level were almost completely reversed by the addition of putrescine to the medium during pretreatment with DFMO or invasion assay but were not affected by exogenous spermidine or spermine. No change in the invasive capacity was observed when the CPAE cells were treated with DFMO and the LC-AH cells with methylglyoxal-bis(guanylhydrazone), an inhibitor of S-adenosylmethionine decarboxylase, which depressed the spermidine and spermine levels but increased the putrescine level in the LC-AH cells. These results suggest that intracellular putrescine modulates the in vitro invasive capacity of LC-AH cells.
Ashida
Y
Y
Department of Biochemistry, University of Tokushima, Japan.
Kido
J
J
Kinoshita
F
F
Nishino
M
M
Shinkai
K
K
Akedo
H
H
Inoue
H
H
D000818:Animals; D001201:Ascites / Q000378:metabolism / Q000473:pathology*; D015317:Biogenic Polyamines / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D000518:Eflornithine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology*; D008935:Mitoguazone / Q000494:pharmacology; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D011700:Putrescine / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects
D015317:Biogenic Polyamines; D008935:Mitoguazone; D011700:Putrescine; D000518:Eflornithine